Exousia Pro, Inc. (OTCID: MAJI), a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, is pleased to announce a significant acceleration in its healthcare vertical with the execution of a third Letter of Intent (LOI) to acquire an established telehealth organization. This third acquisition represents a cornerstone in Exousia’s strategy to build a vertically integrated health ecosystem. By acquiring established telehealth platforms, MAJI is not only securing independent revenue streams but is also gaining immediate access to a vast, built-in network of patients and providers.
Read the full article: Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition //
Source: https://www.globenewswire.com/news-release/2026/02/10/3235529/0/en/Exousia-Pro-Inc-Accelerates-Strategic-Expansion-with-Third-Telehealth-Acquisition-Strengthens-Pathway-to-Low-Cost-Customer-Acquisition.html